공시 • 13h
Abbvie Presents New Data Across Its Blood Cancer Portfolio At Eha 2026
AbbVie announced it will share new data at the European Hematology Association 2026 Congress and will showcase clinical advancements from research programs across multiple blood cancers, including multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Featured data from AbbVie's blood cancer portfolio and pipeline include 21 oral and poster presentations, highlighting the investigational compound etentamig (ABBV-383), and approved therapies, EPKINLY (epcoritamab-bysp) (TEPKINLY in the EU), VENCLEXTA (venetoclax) (VENCLYXTO in the EU) and DECNUPAZ (pivekimab sunirine-pvzy). Key oral presentations of epcoritamab data include: Treatment impact of epcoritamab with lenalidomide and rituximab in relapsed or refractory (R/R) FL. A subgroup analysis of the Phase 3 EPCORE FL-1 trial (NCT05409066) of fixed-duration epcoritamab, in combination with rituximab plus lenalidomide (E+R2) for patients with R/R FL (n=243), was performed to determine if the efficacy benefit and tolerability of E+R2 extended across clinically relevant subgroups, including patients with higher- and lower-risk disease features, compared to R2. Between Follicular Lymphoma International Prognostic Index (FLIPI) subgroups, overall response rate (ORR) was numerically higher with E+R2 compared to R2 (FLIPI 0–2, 96.5% vs 84.8%; FLIPI 3–5, 93.0% vs 72.6%). A similar trend was seen in those with progression of disease less than or equal to two years from the date of initial frontline therapy (POD24). Across the age subgroups, ORR and complete response rates (CRR) for E+R2 and R2 for =65 were (94.3% vs 80.2% and 80.7% vs 44.3%, respectively). EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory) after 2 or more treatments, follicular lymphoma (FL) that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab, and follicular lymphoma (FL) that has come back or that did not respond after 2 or more treatments. EPKINLY for the treatment of DLBCL is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children. EPKINLY can cause serious side effects, including: Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce risk of CRS, one will receive EPKINLY on a step-up dosing schedule (when one receive 2 or 3 smaller step-up doses of EPKINLY before the first full dose during the first cycle of treatment), and one may also receive other medicines before and for 3 days after receiving EPKINLY. If the dose of EPKINLY is delayed for any reason, one may need to repeat the step-up dosing schedule. Neurologic problems that can be serious, and can be life-threatening, and lead to death. Neurologic problems may happen days or weeks after person receive EPKINLY. People with DLBCL or high-grade B-cell lymphoma may be hospitalized after receiving their first full dose of EPKINLY on Day 15 of Cycle 1 due to the risk of CRS and neurologic problems. People with FL may be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS and neurologic problems. EPKINLY can cause other serious side effects, including: Infections that may lead to death. Your healthcare provider will check person for signs and symptoms of infection before and during treatment and treat one as needed if person develop an infection. Person should receive medicines from the healthcare provider before person start treatment to help prevent infection. Low blood cell counts, which can be serious or severe. The healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia and lymphopenia), which can increase the risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems. The healthcare provider will monitor person for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. The healthcare provider may temporarily stop or completely stop treatment with EPKINLY if person develop certain side effects. Before person receive EPKINLY, tell the healthcare provider about all the medical conditions, including if person have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If person receive EPKINLY while pregnant, it may harm your unborn baby. If person is a female who can become pregnant, the healthcare provider should do a pregnancy test before person start treatment with EPKINLY and person should use effective birth control (contraception) during treatment and for 4 months after the last dose of EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after the last dose of EPKINLY. The most common side effects of EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma or FL include CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash, and stomach-area (abdominal) pain. The most common severe abnormal laboratory test results with EPKINLY when used alone include decreased white blood cells, decreased red blood cells, and decreased platelets. The most common side effects of EPKINLY when used together with lenalidomide and rituximab in FL include rash, upper respiratory tract infections, tiredness, injection site reactions, constipation, diarrhea, CRS, pneumonia, COVID-19, and fever. The most common severe abnormal laboratory test results with EPKINLY when used together with lenalidomide and rituximab include decreased white blood cells and decreased platelets. VENCLEXTA is a prescription medicine used to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly diagnosed acute myeloid leukemia (AML) who are 75 years of age or older, or have other medical conditions that prevent the use of standard chemotherapy. It is not known if VENCLEXTA is safe and effective in children. VENCLEXTA can cause serious side effects, including: Tumor lysis syndrome (TLS).
